# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidne...
HC Wainwright & Co. analyst Ed Arce reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and maintains $4.5 price ...
- SEC Filing
Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidne...
HC Wainwright & Co. analyst Ed Arce reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and maintains $4.5 price ...